Biogen Inc.
Biogen Reports 2023 Results and 2024 Guidance
Summary
Biogen Inc. announced its financial results for the fourth quarter and full year 2023, reporting total revenue of $9.8 billion and Non-GAAP diluted EPS of $14.72. The company expects a return to Non-GAAP EPS growth in 2024, guided at $15.00 to $16.00 at the mid-point, representing approximately 5% growth. Key operational highlights include the expansion of the rare disease portfolio with the launch of SKYCLARYS and ZURZUVAE, as well as the co-promotion of LEQEMBI in the U.S. and Japan. Biogen's Fit for Growth program is expected to generate savings of $1 billion gross by 2025.
Profitelligence Alerts
Get alerts for BIIB
Be first to know when Biogen Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Biogen Inc.
Biogen Inc. is a globally recognized biotechnology company committed to discovering, developing, and delivering innovative therapies for neurological diseases. With a focus on serious medical conditions, Biogen creates therapies aimed at treating conditions like multiple sclerosis, Alzheimer's disease, and spinal muscular atrophy. The company invests heavily in research and development to pioneer treatments that improve patients' quality of life and addresses critical unmet medical needs. Biogen's influence spans various therapeutic areas in the healthcare sector, making notable strides in both neurodegenerative and rare diseases. The company's portfolio includes a range of biologics, gene therapy, and small molecule drugs, highlighting its strategic diversity. As a prominent player within the biopharmaceutical industry, Biogen collaborates with academic institutions, research organizations, and other biotech firms to enhance its research pipeline and bring new solutions to market. Biogen's role in the financial markets is underscored by its contributions to healthcare innovation and its impact on global health outcomes. Headquartered in Cambridge, Massachusetts, Biogen continues to leverage its scientific expertise and industry alliances to remain at the forefront of biotechnology, influencing both investors and the broader medical community.
Official SEC Documents
Advertisement